Author:
Geserick P,Drewniok C,Hupe M,Haas T L,Diessenbacher P,Sprick M R,Schön M P,Henkler F,Gollnick H,Walczak H,Leverkus M
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference46 articles.
1. Allen JD, Zhang XD, Scott CL, Boyle GM, Hersey P, Strasser A . (2005). Is Apaf-1 expression frequently abrogated in melanoma? Cell Death Differ 12: 680–681.
2. Bae SI, Cheriyath V, Jacobs BS, Reu FJ, Borden EC . (2007). Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL. Oncogene doi:10.1038/sj.onc.1210655.
3. Buchsbaum DJ, Forero-Torres A, Lobuglio AF . (2007). TRAIL-receptor antibodies as a potential cancer treatment. Future Oncol 3: 405–409.
4. Byers HR, Etoh T, Doherty JR, Sober AJ, Mihm MC . (1991). Cell migration and actin organization in human primary, recurrent cutaneous and metastatic melanoma cell lines. Am J Pathol 139: 423–435.
5. Chawla-Skarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC . (2004). Downregulation of Bcl.2, FLIP or IAPs (XIAP and suvivin) by siRNA sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915–923.
Cited by
90 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献